HarrowHROW
HROW
About: Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
Employees: 382
0
Funds holding %
of 7,310 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.34% less ownership
Funds ownership: 58.49% [Q4 2024] → 58.15% (-0.34%) [Q1 2025]
5% less funds holding
Funds holding: 165 [Q4 2024] → 156 (-9) [Q1 2025]
12% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 58
21% less capital invested
Capital invested by funds: $699M [Q4 2024] → $551M (-$148M) [Q1 2025]
23% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 30
33% less funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 2 (-1) [Q1 2025]
48% less call options, than puts
Call options by funds: $11.9M | Put options by funds: $22.7M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$60
95%
upside
Avg. target
$60
95%
upside
High target
$60
95%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen | 95%upside $60 | Buy Maintained | 12 May 2025 |
Financial journalist opinion
Based on 4 articles about HROW published over the past 30 days
Neutral
Business Wire
1 week ago
Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition. “We are excited to welcome Mike to the Harrow Family. His wealth of exper.
Positive
Seeking Alpha
2 weeks ago
I Am Swimming In Dividends With +7% Yields
Winning in gold requires patience and a steady strategy to use the environment to your advantage. The same holds true for investing. Focus on steady dividends over chasing market hype or short-term gains. We discuss our top fixed-income picks, poised for excellent total returns from rate cuts – Yields +7%.
Neutral
PRNewsWire
3 weeks ago
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
TAIPEI , June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic s uspension) 0.05%. BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain following ocular surgery and is the first new ophthalmic steroid in its class in over 15 years.
Neutral
Business Wire
3 weeks ago
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
NASHVILLE, Tenn. & TAIPEI, Taiwan--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%. BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain.
Positive
Seeking Alpha
1 month ago
Harrow: Epic Growth & Operating Leverage On Full Display
Harrow has successfully leveraged its compounding pharmacy roots to drive rapid branded drug growth. Revenue has grown at a steady 40% CAGR for a decade & EBITDA has grown even more sharply. Management is guiding for this to not only continue, but actually accelerate. Harrow's operating leverage is plainly evident in the data. EBITDA margins have risen sharply as the company has grown, and management has guided for this to accelerate in 2025.
Neutral
Business Wire
1 month ago
Harrow to Present at Two Investor Conferences in May
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May: B. Riley Securities 25th Annual Investor Conference (The Ritz-Carlton, Marina del Rey, CA) Format: Fireside Chat, followed by 1x1 Investor Meetings Date/Time: Wednesday, May 21, 2025, through Thursday, May 22, 2025 Craig-Hallum 22nd Annual Institutional Investor Conference (Depot Rena.
Neutral
Seeking Alpha
1 month ago
Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript
Harrow, Inc. (NASDAQ:HROW ) Q1 2025 Results Conference Call May 9, 2025 8:00 AM ET Company Participants Jamie Webb - Director, Communications & IR Mark Baum - CEO Andrew Boll - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Chase Knickerbocker - Craig Hallum Jeffrey Cohen - Ladenburg Thalmann and Company Yi Chen - H. C. Wainwright Mayank Mamtani - B.
Negative
Zacks Investment Research
1 month ago
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates
Harrow (HROW) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.28 per share a year ago.
Neutral
Business Wire
1 month ago
Harrow Announces First-Quarter 2025 Financial Results
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2025. The Company also posted its first quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and future expectations f.
Neutral
Business Wire
1 month ago
Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, after the market close. The Company will also post its first quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Friday, May 9, 2025, to disc.
Charts implemented using Lightweight Charts™